Investor Presentation - First Six Months of 2021

113 Investor presentation First six months of 2021 Novo Nordisk volume market shares in the three insulin segments NAO USA long-acting insulin USA premix insulin USA fast-acting insulin tMU tMU tMU 100 80% 80 80% 80 100% CAGR volume1: 1.0% MI penetration²: 66.8% CAGR volume¹: (6.9%) MI penetration: 48.1% CAGR volume1: 1.8% MI penetration: 83.7% 80% 80 60% 60 60 60% 60 60 60 40 40 20 20 0 40% 40 40 20% 20 40% 40 20% 20 0% 0 May May 2021 2016 0% 0 May May May 2016 2021 2016 Segment volume Tresiba -Levemir Segment volume Ⓡ Combined NovoLog Mix share 70/30 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units Source: IQVIA monthly MAT, May 2021 volume figures NN: Novo Nordisk Segment volume Ⓡ Fiasp 60% 40% 20% 0% May 2021 -NovoRapid NN combined

View entire presentation